Sulfide Ionizable Lipids for Stable Nucleic Acid Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems, such as lipid-DNA conjugates, face challenges in efficiently delivering anionic drugs like nucleic acids to target organs or cells, causing inflammation and accumulation in non-target tissues.
Innovation Solution
Development of a sulfide-containing ionizable lipid that forms stable complexes with anionic drugs, enabling efficient encapsulation and targeted delivery to the liver or lungs through lipid nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lipid-DNA conjugates are used to deliver nucleic acids, then cellular delivery efficiency is improved, but inflammation and tissue accumulation occur in non-target organs
Solution Approach 1:
The patent modifies the chemical structure of ionizable lipids by introducing sulfide groups at specific positions (e.g., 2-position or 3-position of the piperidine ring). This structural parameter change alters the lipid's interaction properties with nucleic acids and biological systems, enabling efficient cellular delivery while reducing immunogenicity and off-target tissue accumulation compared to conventional lipid-DNA conjugates
Solution Approach 2:
The invention creates composite lipid-nucleic acid structures where sulfide-containing ionizable lipids form stable complexes with anionic nucleic acids through electrostatic interactions. The sulfide group serves as a key functional component that mediates both encapsulation efficiency and reduced biological resistance, achieving dual optimization of delivery performance and safety
2Reliability
If cationic lipids are used to form lipid-DNA conjugates, then nucleic acid binding and cellular uptake are enhanced, but immunogenicity increases
Solution Approach 1:
The patent introduces sulfide groups into the ionizable lipid structure at specific positions, which modifies the electrostatic and steric parameters of the lipid-nucleic acid complex. This parameter modification maintains strong binding affinity and cellular uptake capability while simultaneously reducing recognition by the immune system, thereby lowering immunogenicity compared to traditional cationic lipids
3Ease of manufacture
If conventional lipids are used for drug delivery, then ease of manufacture is maintained, but encapsulation efficiency of anionic drugs is insufficient
Solution Approach 1:
The sulfide-containing ionizable lipids are designed with specific structural parameters (sulfide group position and configuration) that enhance electrostatic interaction with anionic drugs. This parameter optimization significantly improves encapsulation efficiency during nanoparticle formation while maintaining compatibility with conventional manufacturing processes, avoiding the need for complex synthesis procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sulfide-containing ionizable lipid ensures high encapsulation efficiency and stable delivery of anionic drugs, particularly nucleic acids, with reduced immunogenicity and tissue accumulation, as demonstrated by in vitro and in vivo efficacy tests.
Implementation Method 1
A sulfide-containing ionizable lipid of the disclosure interacts electrostatically with an anionic drug when a lipid nanoparticle is produced, thereby ensuring that the drug is encapsulated in the lipid nanoparticle with high efficiency
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The disclosure relates to a novel sulfide-containing ionizable lipid. The ionizable lipid of the disclosure interacts electrostatically with an anionic drug when a lipid nanoparticle is produced, thereby ensuring that the drug is encapsulated in the lipid nanoparticle with high efficiency and the drug is stably delivered into the body, facilitating its utility in the related art such as lipid nanoparticle-mediated gene therapy.